explore -WSS

explore

author：fashion 2025-08-12 11:29:28 - browse：498

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Covid hospitalizations on the rise, Humana says

entertainment

WSS

The 10 drugs up first for Medicare price negotiation

Why doctors need education on FDA device approval process

Think you might have Covid

Crinetics acromegaly drug succeeds in late

Weighted lottery helped low

AI generated plenty of interest at JPM but not a lot of trust

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

New air purifier tech could be key to improving indoor air quality

Why doctors need education on FDA device approval process

BioMarin wins approval for gene therapy to treat hemophilia A

New brain studies show LSD's effects on the brain in full color

Apple is now the first public company to be valued at $3 trillion

'Make People Better': The CRISPR babies story you probably don't know

At least 13 dead in Texas as scorching temps continue

What drug price negotiations mean for Medicare Part D

Activists slam private health insurers over coverage restrictions

House transparency, PBM reform bill gains bipartisan support

entertainment

Medicare Advantage today, explained in one chart

NIH director takes cautious approach to Biden drug pricing priority

Why Novartis is changing the name of its research labs

Parkinson’s finding may lead to tests and, someday, treatments

The surgeon had a dilemma only a Nazi medical text could resolve

Listen: Biogen's potential pivot, & Illumina's next chapter

knowledge

entertainment

entertainment

explore